文献速递肺结节与肺癌

电子鼻呼气图谱诊断非小细胞肺癌的多中心验证研究

Diagnosing Non-Small Cell Lung Cancer by Exhaled Breath Profiling Using an Electronic Nose: A Multicenter Validation Study.
PubMed 文献 · Chest · 2022-10-13

该多中心研究用便携式电子鼻(aeoNose)采集5分钟潮式呼气数据,将呼气数据与临床变量联合建模,在训练集376例中建立肺癌预测模型,并在199例盲法验证集中验证;模型在验证集保持16%概率阈值时敏感度95%、特异度49%、阴性预测值94%,AUC为0.86。

要点

  • 电子鼻联合临床变量诊断NSCLC的验证集敏感度95%、特异度49%、阴性预测值94%。
  • 训练集与验证集AUC分别为0.87和0.86,判别性能一致。
  • 呼气分析为无创手段,但特异度偏低,需结合临床判断。

核心结论

  • 多中心、多设备验证显示,呼气数据联合临床变量可无创区分肺癌与非肺癌受试者。

研究设计与样本

  • 多中心研究,NSCLC患者与对照受试者通过aeoNose手持电子鼻进行5分钟潮式呼吸。
  • 训练集376例用于建立预测模型,验证集199例为盲法验证。
  • 采用多变量逻辑回归分析,纳入呼气数据与临床变量,以肺癌概率16%为截断值。

主要发现

  • 训练集全模型敏感度95%、特异度51%、阴性预测值94%,AUC为0.87。
  • 验证集敏感度95%、特异度49%、阴性预测值94%,AUC为0.86。

关键数值与推荐

  • 肺癌概率截断值为16%。
  • 训练集敏感度95%、特异度51%、阴性预测值94%、AUC 0.87。
  • 验证集敏感度95%、特异度49%、阴性预测值94%、AUC 0.86。

临床怎么用

  • 呼气电子鼻联合临床变量可作为无创辅助手段用于肺癌诊断评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the potential of exhaled breath analysis of volatile organic compounds to diagnose lung cancer, clinical implementation has not been realized, partly due to the lack of validation studies. RESEARCH QUESTION: This study addressed two questions. First, can we simultaneously train and validate a prediction model to distinguish patients with non-small cell lung cancer from non-lung cancer subjects based on exhaled breath patterns? Second, does addition of clinical variables to exhaled breath data improve the diagnosis of lung cancer? STUDY DESIGN AND METHODS: In this multicenter study, subjects with non-small cell lung cancer and control subjects performed 5 min of tidal breathing through the aeoNose, a handheld electronic nose device. A training cohort was used for developing a prediction model based on breath data, and a blinded cohort was used for validation. Multivariable logistic regression analysis was performed, including breath data and clinical variables, in which the formula and cutoff value for the probability of lung cancer were applied to the validation data. RESULTS: A total of 376 subjects formed the training set, and 199 subjects formed the validation set. The full training model (including exhaled breath data and clinical parameters from the training set) were combined in a multivariable logistic regression analysis, maintaining a cut off of 16% probability of lung cancer, resulting in a sensitivity of 95%, a specificity of 51%, and a negative predictive value of 94%; the area under the receiver-operating characteristic curve was 0.87. Performance of the prediction model on the validation cohort showed corresponding results with a sensitivity of 95%, a specificity of 49%, a negative predictive value of 94%, and an area under the receiver-operating characteristic curve of 0.86. INTERPRETATION: Combining exhaled breath data and clinical variables in a multicenter, multi-device validation study can adequately distinguish patients with lung cancer from subjects without lung cancer in a noninvasive manner. This study paves the way to implement exhaled breath analysis in the daily practice of diagnosing lung cancer. CLINICAL TRIAL REGISTRATION: The Netherlands Trial Register; No.: NL7025; URL: https://trialregister.nl/trial/7025.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Kort S, Brusse-Keizer M, Schouwink H, et al. Diagnosing Non-Small Cell Lung Cancer by Exhaled Breath Profiling Using an Electronic Nose: A Multicenter Validation Study. Chest. 2022. PMID: 36243060. doi:10.1016/j.chest.2022.09.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。